ETErcole Tagliamonte

Ercole Tagliamonte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ercole Tagliamonte has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Carlo Romano

    Cardiology Division, "Umberto I" Hospital, Nocera Inferiore, SA, Italy

    3 shared publications
  • Costantino Astarita

    Cardiology Division, Santa Maria della Misericordia Hospital, Sorrento, Naples, Italy

    3 shared publications
  • Fausto Rigo

    Department of Cardiology, Division of Cardiology, dell'Angelo Hospital, Mestre-Venice, Italy

    3 shared publications
  • Nicola Capuano

    Cardiology Division, "Umberto I" Hospital, Nocera Inferiore, SA, Italy

    3 shared publications
  • Teresa Cirillo

    Cardiology Division, "Umberto I" Hospital, Nocera Inferiore, SA, Italy

    3 shared publications
  • Alberto Forni

    Department of Cardiology and Intensive Coronary Care, Umberto I Hospital, Nocera Inferiore, Italy

    2 shared publications

Latest Publications

  • Open Access

    The Incremental Role of Multiorgan Point-of-Care Ultrasounds in the Emergency Setting

    by Antonello D’andrea, Carmen Del Giudice, Dario Fabiani, Adriano Caputo, Francesco Sabatella, Luigi Cante, Stefano Palermi, Alfonso Desiderio, Ercole Tagliamonte, Biagio Liccardo, et al.

    Point-of-care ultrasonography (POCUS) represents a goal-directed ultrasound examination performed by clinicians directly involved in patient healthcare. POCUS has been widely used in emergency departments, where US exams allow physicians to make quick diagnoses and to recognize early life-threatening conditions which require prompt interventions. Although initially meant for the real-time evaluation of cardiovascular and respiratory pathologies, its use has been extended to a wide range of clinical applications, such as screening for deep-vein thrombosis and trauma, abdominal ultrasonography of the right upper quadrant and appendix, and guidance for invasive procedures. Moreover, recently, bedside ultrasounds have been used to evaluate the fluid balance and to guide decongestive therapy in acutely decompensated heart failure. The aim of the present review was to discuss the most common applications of POCUS in the emergency setting.


  • Coronary microvascular dysfunction affects left ventricular global longitudinal strain response to dipyridamole stress echocardiography: a pilot study

    by Ercole Tagliamonte, Simona Sperlongano, Caterina Montuori, Lucia Riegler, Raffaella Scarafile, Andreina Carbone, Alberto Forni, Juri Radmilovic, Alessandro Di Vilio, Roberta Astarita, et al.

    The aim is to investigate, by means of speckle tracking echocardiography, left ventricular (LV) contractile function at rest and during dipyridamole stress in patients with coronary microvascular dysfunction (CMD). 59 patients (39% women, mean age 65.6 ± 6.1 years) with history of chest pain and without obstructive coronary artery disease (CAD) underwent dipyridamole stress echocardiography. Coronary flow was assessed in the left anterior descending coronary artery. Coronary flow reserve (CFR) was determined as the ratio of hyperaemic to baseline diastolic coronary flow velocity. CMD was defined as CFR < 2. Global longitudinal strain (GLS) was measured at rest and at peak dose. Nineteen patients (32%) among the overall population showed CMD. Baseline GLS was significantly lower in patients with CMD (– 16.8 ± 2.7 vs. – 19.1 ± 3.1, p < 0.01). A different contractile response to dipyridamole infusion was observed between the two groups: GLS significantly increased up to peak dose in patients without CMD (from – 19.1 ± 3.1 to – 20.2 ± 3.1, p < 0.01), and significantly decreased in patients with CMD (from – 16.8 ± 2.7 to – 15.8 ± 2.7, p < 0.01). There was a significant inverse correlation between CFR and ∆GLS (r = – 0.82, p < 0.01). Rest GLS and GLS response to dipyridamole stress are markedly impaired among patients with chest pain syndrome, non-obstructive CAD and CMD, reflecting subclinical LV systolic dysfunction and lack of LV contractile reserve due to underlying myocardial ischemia.


  • Open Access

    Coronary microvascular dysfunction affects left ventricular global longitudinal strain response to dipyridamole stress echocardiography: a pilot study

    by Ercole Tagliamonte, Simona Sperlongano, Caterina Montuori, Lucia Riegler, Raffaella Scarafile, Andreina Carbone, Alberto Forni, Juri Radmilovic, Alessandro Vilio, Roberta Astarita, et al.

    Aim: to investigate, by means of speckle tracking echocardiography, left ventricular (LV) contractile function at rest and during dipyridamole stress in patients with coronary microvascular dysfunction (CMD). Methods and Results: 59 patients (39% women, mean age 65.6 ± 6.1 years) with history of chest pain and without obstructive coronary artery disease (CAD) underwent dipyridamole stress echocardiography. Coronary flow was assessed in the left anterior descending coronary artery. Coronary flow reserve (CFR) was determined as the ratio of hyperaemic to baseline diastolic coronary flow velocity. CMD was defined as CFR < 2. Global longitudinal strain (GLS) was measured at rest and at peak dose. Nineteen patients (32%) among the overall population showed CMD. Baseline GLS was significantly lower in patients with CMD (-16.8 ± 2.7 vs. -19.1 ± 3.1, p < 0.01). A different contractile response to dipyridamole infusion was observed between the two groups: GLS significantly increased up to peak dose in patients without CMD (from -19.1 ± 3.1 to -20.2 ± 3.1, p < 0.01), and significantly decreased in patients with CMD (from -16.8 ± 2.7 to -15.8 ± 2.7, p < 0.01). There was a significant inverse correlation between CFR and DGLS (r = -0.82, p < 0.01).Conclusion: rest GLS and GLS response to dipyridamole stress are markedly impaired among patients with chest pain syndrome, non-obstructive CAD and CMD, reflecting subclinical LV systolic dysfunction and lack of LV contractile reserve due to underlying myocardial ischemia.

  • Open Access

    Ivabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate

    by Ercole Tagliamonte, Teresa Cirillo, Fausto Rigo, Costantino Astarita, Antonino Coppola, Carlo Romano, Nicola Capuano

    Introduction Coronary flow velocity reserve (CFVR) is an important prognostic marker in patients with stable coronary artery disease (CAD). Beta-blockers and ivabradine have been shown to improve CFVR in patients with stable CAD, but their effects were never compared. The aim of the current study was to compare the effects of bisoprolol and ivabradine on CFVR in patients with stable CAD. Methods Patients in sinus rhythm with stable CAD were enrolled in this prospective, randomized, double-blind trial. Patients had to be in a stable condition for at least 15 days before enrollment, on their usual therapy. Patients who were receiving beta-blockers or ivabradine entered a 2-week washout period from these drugs before randomization. Transthoracic Doppler-derived CFVR was assessed in left anterior descending coronary artery, and was calculated as the ratio of hyperemic to baseline diastolic coronary flow velocity (CFV). Hyperemic CFV was obtained using dipyridamole administration using standard protocols. After CFVR assessment, patients were randomized to ivabradine or bisoprolol and entered an up-titration phase, and CFVR was assessed again 1 month after the end of the up-titration phase. Results Fifty-nine patients (38 male, 21 female; mean age 69 ± 9 years) were enrolled. Transthoracic Doppler-derived assessment of CFV and CFVR was successfully performed in all patients. Baseline characteristics were similar between the bisoprolol and ivabradine groups. No patient dropped out during the study. At baseline, rest and hyperemic peak CFV as well as CFVR was not significantly different in the ivabradine and bisoprolol groups. After the therapy, resting peak CFV significantly decreased in both the ivabradine and bisoprolol groups, but there was no significant difference between the groups (ivabradine group 20.7 ± 4.6 vs. 22.8 ± 5.2, P < 0.001; bisoprolol group 20.1 ± 4.1 vs. 22.1 ± 4.3, P < 0.001). However, hyperemic peak CFV significantly increased in both groups, but to a greater extent in patients treated with ivabradine (ivabradine: 70.7 ± 9.4 vs. 58.8 ± 9.2, P < 0.001; bisoprolol: 65 ± 8.3 vs. 58.7 ± 8.2, P < 0.001). Accordingly, CFVR significantly increased in both groups (ivabradine 3.52 ± 0.64 vs. 2.67 ± 0.55, P < 0.001; bisoprolol 3.35 ± 0.70 vs. 2.72 ± 0.55, P < 0.001), but it was significantly higher in ivabradine group, despite a similar decrease in heart rate (63 ± 7 vs. 61 ± 6; P not significant). Conclusion Ivabradine improves hyperemic peak CFV and CFVR to a greater extent than bisoprolol in patients with stable CAD, despite a similar decrease in heart rate. These data demonstrate that the benefits from ivabradine therapy go beyond the heart rate. This could be due to a different mechanism such as diastolic perfusion time, isovolumic ventricular relaxation, end-diastolic pressure, and collaterals. Funding Servier.


  • Effects of Ranolazine on Noninvasive Coronary Flow Reserve in Patients with Myocardial Ischemia But without Obstructive Coronary Artery Disease

    by Ercole Tagliamonte, Fausto Rigo, Teresa Cirillo, Costantino Astarita, Gaetano Quaranta, Umberto Marinelli, Archimede Caruso, Carlo Romano, Nicola Capuano

    Introduction: Ranolazine reduces the Na‐dependent calcium overload via inhibition of the late sodium current, improving diastolic tone and oxygen handling during myocardial ischemia. In patients with angina, evidence of myocardial ischemia, but no obstructive coronary artery disease (CAD), abnormal coronary autoregulation plays a key role. Transthoracic Doppler–derived coronary flow reserve (CFR) is an index of coronary arterial reactivity and decreases in both microvascular dysfunction and coronary artery stenosis. The aim of this study was to assess the effect of ranolazine on CFR in this group of patient.Methods: Fifty‐eight (39M, 19F) patients with angina and evidence of myocardial ischemia, but no obstructive CAD, were enrolled in a double‐blind, placebo‐controlled trial. Participants were assigned to ranolazine (29) or placebo (29) for 8 weeks (up to 500 mg twice a day). CFR was determined as the ratio of hyperemic, induced by intravenous dypiridamole administration, to baseline diastolic coronary flow velocity. CFR was assessed before and after 8‐week therapy.Results: CFR was successfully performed in all patients. There were no significant differences in baseline characteristics and CFR between ranolazine and placebo group. After 8 weeks CFR significantly increased in ranolazine group (2.54 ± 0.44 vs. 1.91 ± 0.31; P = 0.005) but not in placebo group (1.99 ± 0.32 vs. 1.94 ± 0.29; P = ns). No patient dropped out during 8 weeks therapy. Side effects were similar in both groups.Conclusions: Ranolazine is able to improve CFR in these patients. This is probably due to improvement in abnormal coronary autoregulation, both reducing baseline diastolic coronary flow velocity and increasing hyperemic diastolic coronary flow velocity.


  • COMPARISON OF THE EFFICACY OF BISOPROLOL AND IVABRADINE ON DOPPLER DERIVED CORONARY FLOW RESERVE IN PATIENTS WITH STABLE ANGINA PECTORIS: BEYOND THE HEART RATE

    by Ercole Tagliamonte, Fausto Rigo, Teresa Cirillo, Costantino Astarita, Umberto Marinelli, Archimede Caruso, Gerardo Riccio, Carlo Romano, Nicola Capuano